BOSTON, November 20, 2025 — Leads & Copy — Curium, a radiopharmaceutical producer, and CapVest Partners LLP (CapVest), a global investment firm, announced the recapitalization of Curium through a new Continuation Vehicle (CV), valuing Curium at approximately $7 billion.
The transaction garnered support from existing and new institutional investors in the US, Europe, the Middle East, and APAC, including lead investors ICG, TPG GP Solutions, and CVC Secondary Partners, with additional investments from Goldman Sachs Alternatives, Lunate, Pantheon, and Ardian. Curium also obtained a minority investment from TPG Life Sciences Innovations.
TPG’s life sciences platform targets companies developing science to improve patient outcomes in high-need areas, according to the release. The investor base reflects confidence in Curium’s growth and innovation, and in the market’s projected growth over the next 15 years.
Over the past decade, Curium has become a global leader in nuclear medicine, with a vertically integrated supply chain delivering diagnostic and therapeutic radiopharmaceuticals to over 14 million patients in more than 70 countries across six continents each year.
Curium’s portfolio includes diagnostic radiopharmaceuticals and a pipeline of Radioligand Therapies (RLTs) that target neuroendocrine and prostate cancers.
The new CV will increase Curium’s financial resources to support the next growth phase. The company plans to continue launching diagnostic and therapeutic solutions for cancer patients and develop next-generation radiopharmaceuticals through internal development, acquisitions, or partnerships.
The transaction is expected to close in Q1 2026, pending regulatory approvals, with CapVest remaining Curium’s controlling shareholder.
Curium CEO Renaud Dehareng said that the transaction and investor interest endorses Curium’s position as the largest independent nuclear medicine platform. He added that the transaction positions the company to accelerate its global strategy and product launches to deliver solutions for healthcare professionals and patients.
Kate Briant, Senior Partner at CapVest, stated that Curium is well-positioned to play a major role in an industry expected to double in size over the next five years and then again.
PJT Partners served as lead financial advisor, and Kirkland & Ellis served as lead legal advisor for the transaction.
Curium is headquartered in Boston and has offices worldwide. With over 3,000 employees and four manufacturing sites, including two in the United States, Curium supplies radiopharmaceuticals globally.
Camilla Campell
VP, Head of Global Communications
Camilla.campbell@curiumpharma.com
Ben Valdimarsson
Reputation Inc.
bvaldimarsson@reputation-inc.com
Source: Curium
